MaxCyte launches share issue to raise at least £10n

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 07:34

Cell-based medicines company MaxCyte Group launched a share issue to raise at least £10.0m to fund an acceleration of its growth strategy.

New shares in the company would be issued at 170p each.

MaxCyte said the raising would support an expansion of its cell-therapy pipeline and the formation of clinical and commercial deals.


Related content

MaxCyte inks commercial licensing agreement with Editas Medicine

Cell-based therapies developer MaxCyte said it had signed a commercial license agreement with genome editing company Editas Medicine.

Editas Medicine would use MaxCyte's Flow Electroporation...

Mon, 07/10/2019 - 07:45


MaxCyte losses deepen after higher R&D spend

Cell-based therapies and life sciences company MaxCyte booked a deeper first-half loss after rising revenue was more than offset by higher R&D and marketing costs....

Wed, 18/09/2019 - 14:33


MaxCyte sees first-half revenue rising 21%

Cell-based therapies company MaxCyte said its revenue in the first half was expected to grow by 21%.

Revenue for the six months through June was...

Wed, 17/07/2019 - 07:52


MaxCyte initiates dosing for second cohort of patients in cancer treatment trial

MaxCyte said it had initiated dosing for the second cohort of patients in a clinical trial of a treatment for ovarian cancer and peritoneal mesothelioma....

Wed, 08/05/2019 - 07:55


MaxCyte books annual loss owing to R&D, marketing spending

Cell-based medicines group MaxCyte booked a full-year loss after rising sales were more than offset by spending, including on R&D and marketing.

Net losses for...

Wed, 24/04/2019 - 07:52